Please select the eligibility criteria that correspond to the clinical trial below.
Title: Gender Differences in the Development and Prognosis of Coronary Disease Where Initial Disease Manifestation is Stable Angina, Myocardial Infarction or Unheralded Coronary Death: A CALIBER Study Using Linked GPRD-MINAP Data
Brief Summary: The initial manifestation of symptomatic coronary disease can range from angina (or symptoms of angina), unheralded acute coronary syndrome (ACS), or unheralded coronary death. A better understanding of gender differences in initial presentation of coronary disease and the rate and predictors of progression to subsequent stages in coronary disease could help to identify which gender- specific factors might reduce or slow transition to more serious disease states and improve outcomes. The investigators' research focuses on the role primary care management of cardiovascular risk factors plays in gender differences in the progression to subsequent disease states and to mortality.


Options:
A: Inclusion Criteria:

* Essential hypertension

Exclusion Criteria:

* Severe hypertension.
* Secondary hypertension.
* Grade III/IV hypertensive retinopathy.
* Type 1 diabetes.
* Cerebrovascular or cardiovascular event during the last 12 months prior to inclusion.
* Pregnant or lactating females.
* History of malignancy within the past five years.
* Shift workers.
* Obstructive sleep apnea.
* Use of disallowed concomitant medication.
* Intolerant to ABPM.
B: Inclusion Criteria:

* Male or female subjects ≥18 years of age.
* High-normal BP or essential hypertension.
* Any subject with recommendation for evaluation with ABPM according to the 2007 European Guidelines.
* Informed consent to participate in the study prior to any study procedures.

Exclusion Criteria:

* Known or suspected contraindications to any potential medication under investigation.
* Shift-workers.
* Inability to communicate and comply with all study requirements.
* Persons directly involved in the execution of this protocol.
* Intolerants to the use of the ABPM device.
C: Inclusion Criteria:

* as above

Exclusion Criteria:

* patients with a history of ischaemic heart disease, heart failure, cerebrovascular disease, peripheral arterial disease or congenital coronary anomalies, prior to entry into the cohort
* patients with symptoms of chest pain in the 6 months prior to cohort entry
* patients \< 35 or \>100 years of age after eligibility for entry to the cohort
D: Inclusion Criteria:

- Hypertension defined by a MSSBP \>=150 mmHg (untreated patients) or patients on current anti-hypertensive treatment who remain uncontrolled (i.e. MSSBP \>140 mmHg)

* Randomisation mean 24h blood pressure above 130/80 mmHg
* In addition the patients must fulfill, at least, one of the following criteria:

Controlled type II Diabetes mellitus Hypercholesteremia, currently treated with lipid-lowering drugs Metabolic syndrome MI, CABG or PTCA more than one year ago Stroke or transient ischemic cerebral attack more than one year ago Documented history of peripheral vascular disease, increased IMT, or carotid plaques Documented history of LVH Elderly \>65 years

Exclusion Criteria:

* - MSSBP \>=180 mmHg and/or MSDBP \>= 110 mmHg at any time from Visit 1 to Visit 3
* Inability to discontinue all prior anti-hypertensive medications safely for a period of three weeks
* Mandatory indication for any concomitant medication for coronary artery disease or any other disease that is not allowed during this study.

Other protocol-defined exclusion criteria may apply.

Answer: C